Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Feng Xu(Shanghai Sixth People's Hospital), Liyu Zhou(Shanghai Sixth People's Hospital)
Scientific Reports
December 4, 2014
Cited by 49


Related Papers